

Specialty Guideline Management

Lymphir

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Lymphir	denileukin diftitox-cxdl

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Compendial Uses²

Mycosis fungoides (MF) – primary treatment

All other indications are considered experimental/investigational and not medically necessary.

Reference number(s)
6612-A

Coverage Criteria

Cutaneous T-Cell Lymphoma^{1,2}

Authorization of 12 months may be granted for treatment of stage I-III cutaneous T-cell lymphoma.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Lymphir [package insert]. Cranford, NJ: Citius Pharmaceuticals, Inc.; August 2024.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed December 15, 2025.